Politics / Law

Sector calls for more transparency

04.11.2010

Parma/Brussels – Four years ago, the EU Council and European Parliament adopted the Health Claims Regulation to ban food claims that could mislead consumers. At the end of October, members of the Federation of European Specialty Food Ingredients Industries (ELC) were questioning whether the Regulation is meeting that goal. Prior to the ELC statement, the EFSA announced that it has now evaluated 1,745 claims from a list of 4,637 generic health claims, as well as about 100 out of 300 claims on disease prevention. “Only 5 % of the claims received a positive opinion,”said ELC president Prof. Dr. Markwart Kunz. “A rejection rate of 95 % calls into question whether the criteria applied are appropriate.”
Criticism from scientists and companies also grew louder after the latest evaluation round, when only 75 out of 808 pooled health claims received positive evaluations from the EFSA’s NDA panel. While the body said the high attrition rate was attributable to the poor quality of applications, even companies whose health claims were granted said there was a lack of transparency about the criteria for evaluation. “We are evaluating case-by-case,” explained an EFSA spokesman. However researchers from Cognis, which received approvals for two health claims in the latest evaluation round, told EuroBiotechNews that there are currently no defined criteria concerning either the number of clinical studies required for approval, or their minimum size and design. They added that “there is a lot of uncertainty in the industry, and many companies hope this will improve with the publication of guidelines that say more than that every claim is to be analysed case-by-case.” Food expert Andreas Hahn from the University of Hanover said that health claims are being evaluated on a very high level at EFSA. “It’s a matter of debate if the level of evidence demanded by EFSA is appropriate for the approval of an advertising claim,” he said. According to Hahn, the current evaluation practice poses a threat to most SMEs developing functional foods, because when it comes to innovative approaches, the success rate at the EFSA is very low.

Innovation not rewarded

Currently, the British SME Provexis is the only exception. Its 12 employees recently licensed their Fruitflow® tomato extract to DSM Nutritional Products following the approval of the claim that the functional ingredient prevents platelet aggregation. According to COO Steve Morrison, platelet aggregation was a very specific endpoint that could be determined accurately. In cases where hard endpoints like heart in­farction or neurological degeneration can’t be determined, companies have to rely on surrogate markers. “It is very difficult to correlate bio­markers with a health effects,” said Werner Klaffke, Director of Nutrition & Health at Unilever, “even for large companies.”

Politics / Law

06.03.2012

London – The European Medicines Agency (EMA) calls it “the biggest change to the legal framework since the establishment of the Agency in 1995.” This year, the EU drug regulators are preparing new so-called pharmacovigilance...

Clinical Trial

06.03.2012

Norway’s Algeta ASA (Oslo) has updated its Phase III survival analysis of Alpharadin in patients with castration-resistant prostate cancer and bone metastases. The analysis showed an increase of 3.6 months in median overall...

Clinical Trial

06.03.2012

Genticel S.A. (Toulouse) has completed enrolment in its Phase Ib study of a lyophilised version of the world’s very first therapeutic vaccine ProCervix, which inhibits infection with the cancer-causing Human Papilloma Virus. The...

Clinical Trial

06.03.2012

The share value of French specialist for cardiometabolic diseases Genfit S.A. (Loos/Lille) took a jump after the company announced its candidate drug GFT505 had met all efficacy endpoints in a pilot Phase II study involving 22...

Clinical Trial

06.03.2012

The US Food and Drug Administration (FDA) has granted a Biologics License Application (BLA) to the HER2 dimerisation inhibitor pertuzumab developed by Roche (Basel) for previously untreated HER2­-positive metastatic breast...

Politics / Law

06.03.2012

A For years, the world’s major patent offices – including the EPO, USPTO and JPO – have been collaborating in the Patent Prosecution Highway (PPH) programme. Under the PPH, an applicant whose claims have been allowed in one...

BioFunding

06.03.2012

Berlin/Dublin – Two EU initiatives are seeking to better predict response to cancer treatments. Researchers from the a6m RESPONSIFY Project will develop biomarker-based breast cancer prognosis tests that could be used to predict...

BioFunding

06.03.2012

Bremen/Brussels – European researchers kicked-off the MicroB3 (Bio­diversity, Bioinformatics, Biotechnology) project in February. Thanks to a a9m EU fund, the 32 groups involved will create a unique bioinformatic resource that...

BioFunding

06.03.2012

A Brussels – The European Commission is boosting its investments and policy activities to foster sustainability. “Europe needs to make the transition to a post-petroleum economy,” said Máire Geoghegan-Quinn in Brussels. In...

Politics / Law

06.03.2012

Brussels – In February, I heard of a slightly mad and very worrying trend in decisions handed down by the Court of Justice of the European Union (CJEU) with regard to IP issues handed up from the national level for clarification....

Displaying results 11 to 20 out of 1982

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/1/article/sector-calls-for-more-transparency.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.48 EUR3.77%
  • 4SC1.12 EUR2.75%
  • VITA 344.00 EUR2.04%

FLOP

  • ADDEX2.99 CHF-7.14%
  • BIOFRONTERA2.18 EUR-5.22%
  • SARTORIUS94.26 EUR-3.32%

TOP

  • SANTHERA92.00 CHF43.5%
  • CO.DON3.02 EUR26.9%
  • PAION2.98 EUR19.7%

FLOP

  • EVOTEC3.00 EUR-20.0%
  • ADDEX2.99 CHF-18.5%
  • 4SC1.12 EUR-15.8%

TOP

  • SANTHERA92.00 CHF2211.6%
  • CO.DON3.02 EUR247.1%
  • PAION2.98 EUR189.3%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.23 EUR-41.4%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 16.09.2014


Current issue

All issues

Product of the week

Products